In another randomized phase II/III study, the primary outcome was to evaluate the use of trastuzumab and hyaluronidase-oysk or a fixed dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf in combination with paclitaxel/carboplatin in patients with HER2-amplified USC or carcinosarcoma. The gene discussed is ERBB2; the disease is carcinosarcoma.